Efficient	O
inhibition	O
of	O
ovarian	B-Cancer
cancer	I-Cancer
growth	O
and	O
prolonged	O
survival	O
by	O
transfection	O
with	O
a	O
novel	O
pro	O
-	O
apoptotic	O
gene	O
,	O
hPNAS	O
-	O
4	O
,	O
in	O
a	O
mouse	O
model	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
results	O
.	O

OBJECTIVE	O
:	O
We	O
transfected	O
ovarian	B-Cell
cancer	I-Cell
cells	I-Cell
and	O
administered	O
recombinant	O
plasmid	B-Cellular_component
encoding	O
hPNAS	O
-	O
4	O
to	O
nude	O
mice	O
bearing	O
ovarian	B-Cancer
cancer	I-Cancer
,	O
aiming	O
to	O
evaluate	O
the	O
effect	O
of	O
hPNAS	O
-	O
4	O
against	O
ovarian	B-Cancer
cancer	I-Cancer
in	O
vitro	O
and	O
in	O
vivo	O
.	O

METHODS	O
:	O
Ovarian	B-Cell
cancer	I-Cell
SKOV3	I-Cell
cells	I-Cell
were	O
transfected	O
with	O
hPNAS	O
-	O
4	O
-	O
plasmid	B-Cellular_component
,	O
and	O
cell	B-Cell
proliferation	O
was	O
evaluated	O
by	O
MTT	O
assay	O
;	O
apoptosis	O
was	O
examined	O
by	O
DNA	O
ladder	O
,	O
Hoechst33258	O
staining	O
and	O
flow	O
-	O
cytometric	O
assays	O
.	O

Nude	O
mice	O
bearing	O
ovarian	B-Cancer
cancers	I-Cancer
were	O
treated	O
with	O
hPNAS	O
-	O
4	O
-	O
p	O
/	O
liposome	B-Cellular_component
.	O

Tumor	B-Cancer
growth	O
was	O
determined	O
and	O
survival	O
was	O
recorded	O
.	O

TUNEL	O
assay	O
and	O
microvessel	B-Tissue
density	O
was	O
assessed	O
to	O
evaluate	O
apoptosis	O
and	O
angiogenesis	O
.	O

RESULTS	O
:	O
Both	O
inhibition	O
of	O
proliferation	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
induction	O
of	O
apoptosis	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
were	O
observed	O
in	O
SKOV3	B-Cell
cells	I-Cell
transfected	O
with	O
hPNAS	O
-	O
4	O
-	O
p	O
in	O
vitro	O
.	O

In	O
hPNAS	O
-	O
4	O
-	O
p	O
-	O
treated	O
tumor	B-Cell
cells	I-Cell
in	O
vivo	O
,	O
tumor	B-Cancer
growth	O
significantly	O
decreased	O
,	O
while	O
the	O
survival	O
time	O
of	O
tumor	B-Cancer
-	O
bearing	O
mice	O
was	O
prolonged	O
compared	O
with	O
control	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Increased	O
apoptosis	O
of	O
tumor	B-Cell
cells	I-Cell
and	O
decreased	O
angiogenesis	O
in	O
tumor	B-Tissue
tissue	I-Tissue
were	O
also	O
observed	O
.	O

CONCLUSIONS	O
:	O
Our	O
promising	O
results	O
on	O
the	O
potential	O
antitumor	B-Cancer
effects	O
of	O
hPNAS	O
-	O
4	O
on	O
ovarian	B-Cancer
cancer	I-Cancer
in	O
vitro	O
and	O
in	O
vivo	O
may	O
be	O
explained	O
,	O
in	O
part	O
,	O
by	O
the	O
induction	O
of	O
apoptosis	O
and	O
inhibition	O
of	O
angiogenesis	O
.	O

Consequently	O
,	O
hPNAS	O
-	O
4	O
has	O
potential	O
as	O
a	O
new	O
gene	O
therapy	O
for	O
human	O
ovarian	B-Cancer
cancer	I-Cancer
.	O

